Some Primary Care Doctors Not Prepared to Help with Cancer Treatment Decisions

Up to one-third of primary care providers discussed breast cancer treatment options with patients but many report gaps in their knowledge.

8:19 AM

Author | Nicole Fawcett

Doctor with patient

The idea of team-based cancer care most often focuses on involving primary care physicians in the care of cancer survivors. But research has shown patients are discussing initial cancer treatment options with their primary care doctors.

And now a new study finds that a significant number of these physicians report notable gaps in their knowledge of cancer treatment options.

"Primary care physicians may be involved in cancer care earlier than we thought. If we are going to promote their involvement, we may need to start doing that earlier, around the time of initial treatment, and ensure PCPs have the information they need to effectively participate in the decision-making process," says Lauren P. Wallner, Ph.D., MPH, a health services researcher at the University of Michigan Rogel Cancer Center.

Wallner and colleagues from the Cancer Surveillance and Outcomes Research Team surveyed 517 primary care physicians who were linked to 1,077 women treated for early stage breast cancer. Physicians were asked whether they had discussed surgery, radiation or chemotherapy options with their patients. They were also asked how comfortable they were discussing these issues and whether they  had the knowledge to help with treatment decisions.

We found that among those involved, some PCPs felt they did not have the knowledge necessary to participate in these treatment decisions,
Lauren P. Wallner, Ph.D., MPH

Researchers found that 34 percent of physicians had discussed surgery options with their patients, 23 percent had discussed radiation and 22 percent had discussed chemotherapy.

Physicians who reported more comfort with cancer treatment discussions were more likely to have these discussions. But, among those physicians who reported involvement in surgery decisions, 22 percent said they were not comfortable having that discussion and 17 percent said they did have the necessary knowledge. Similar findings played out for radiation and chemotherapy. Results are published in Cancer.

"We found that among those involved, some PCPs felt they did not have the knowledge necessary to participate in these treatment decisions. If they're going to be involved, we need to find a way to make sure they have the knowledge to do so, and we support them in a way that ensures they're confident and able to do so," says Wallner, an assistant professor of general medicine and epidemiology at U-M.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily audio updates on iTunesGoogle Play and Stitcher.

The study follows up on a 2016 paper that found one-third of breast cancer patients said they consulted their primary care doctor about treatment options.

"We were all quite surprised that many patients said PCPs were involved. This work stems from those findings. We wanted to understand what decisions providers were involved with and how they perceived their involvement," Wallner says.

The study did not address what patients discussed or how detailed those discussions were. And as such, Wallner emphasizes that the nature of these conversations and how they influence treatment choices is not yet clear.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

But, she says, helping patients better understand the risks and benefits of treatment options is a good thing. For patients who have a longstanding relationship with their primary care doctor, that physician may have a good grasp of the patient's values and preferences and may be able to help the patient navigate these decisions.

"This is an emerging challenge for primary care providers," Wallner says. "Inundating them with detailed information about all possible cancer treatments is not feasible. But these providers are likely to start becoming even more involved with the more prevalent cancers, such as breast or prostate cancer. They need to have sufficient resources and support to be prepared for these conversations."


More Articles About: Industry DX Breast cancer Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Radiation therapy of young women breast cancer
Health Lab
Physicians Don’t Always Recognize Patients’ Radiation Therapy Side Effects
A new study finds that significant side effects were under-recognized in both younger patients and Black patients being treated for breast cancer.
Breast cancer graphics
Health Lab
How Hereditary Genetic Testing Results Impact Breast Cancer Treatment
Breast cancer patients who test positive for an inherited genetic mutation, such as having the BRCA1 or BRCA2 gene, may be receiving treatment based on future cancer risk, rather than guideline approved treatments for their diagnosed cancers, study finds.
Health Lab
‘When Are We Going to Cure Cancer?’: The Bright Future of Breast Cancer Research
When will we cure breast cancer? See how breast cancer treatment has evolved since 1960 and find out what the future of breast cancer treatment and research holds.
Health Lab
Some Breast Cancer Patients Don’t Need Radiation. Why Are They Still Getting It?
Read the findings from a new study examining overtreatment of breast cancer, specifically why many women receive radiation therapy they may not actually need.
A patient considering a contralateral prophylactic mastectomy
Health Lab
Study Finds ‘Striking’ Use of Double Mastectomy
One in six early stage breast cancer patients choose double mastectomy. Learn about unnecessary bilateral mastectomy and why patients choose to have it.
Illustration depicting women's scores on the 21-gene recurrence score assay
Health Lab
Precision Medicine Test for Breast Cancer Helps Guide Chemotherapy Decisions
Learn how oncologists are personalizing breast cancer treatment, including whether or not chemotherapy is used, based on the 21 gene recurrence score assay test.